Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.

International journal of oncology - 1 Nov 2018

Zhang Zheying, Fang Cheng, Wang Yongxia, Zhang Jinghang, Yu Jian, Zhang Yongxi, Wang Xianwei, Zhong Jiateng

Abstract excerpt

Colorectal cancer (CRC) treatment primarily relies on chemotherapy along with surgery, radiotherapy and, more recently, targeted therapy at the late stages. However, chemotherapeutic drugs have high cytotoxicity, and the similarity between the effects of these drugs on cancerous and healthy cells limits their wider use in clinical settings. Targeted monoclonal antibody treatment may compensate for this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Collagen Type I
Share to Collagen Type I, alpha 1 Chain

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Knockout Techniques

Share to Molecular Targeted Therapy

Share to NIMA-Related Kinases

Share to Protein Interaction Maps

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins p21(ras)

Source

Open in PubMed Open full text

Identifiers

PMID: 30132520
DOI: 10.3892/ijo.2018.4536
PMCID: PMC6192778

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.PMID 30132520Read ↗

Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer AnalysisSemantic proximity Read ↗

Exploring the Differential Expression and Prognostic Significance of the COL11A1 Gene in Human Colorectal Carcinoma: An Integrated Bioinformatics ApproachSemantic proximity Read ↗

High expression of COL10A1 is associated with poor prognosis in colorectal cancerSemantic proximity Read ↗

Collagen 1A1 (COL1A1) Is a Reliable Biomarker and Putative Therapeutic Target for Hepatocellular Carcinogenesis and MetastasisSemantic proximity Read ↗

Clinical Significance of COL11A1 and Its Effect on Immune Infiltration in Colorectal CancerSemantic proximity Read ↗

Overexpression of COL4A1 promotes progression of colon cancer and is associated with poor prognosisSemantic proximity Read ↗

KRAS and H1F1a expression in colorectal cancer and its association with the tumor clinicopathological featuresSemantic proximity Read ↗

Identification of Issue Inhibitor of Metalloproteinase 1 (TIMP1) as a Potential Biomarker for the Diagnosis, Pathogenesis and Prognosis of Colorectal Cancer via Integrated Bioinformatic AnalysisSemantic proximity Read ↗

Unraveling TIMP1: a multifaceted biomarker in colorectal cancerSemantic proximity Read ↗

Evaluation of the Prognostic Value of Four ECM-Associated Genes in Recurrence and Metastasis of Colorectal CancerSemantic proximity Read ↗

TIMP1, a promising target of tumor development diagnosis and treatment for colorectal cancerSemantic proximity Read ↗

Epithelial but not stromal expression of collagen alpha-1(III) is a diagnostic and prognostic indicator of colorectal carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.